There are multiple treatment options becoming available for diffuse large B-cell lymphoma, but more work needs to be done to understand their efficacy and in what lines of therapy they should be used.
Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.
Global Bispecific Antibodies Market Size Antibodies Sales Forecast | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
Janssen, a Johnson & Johnson company, has announced that its bispecific antibody has been granted approval by the European Commission (EC) for use in certain patients with relapsed or refractory multiple myeloma (RRMM).
Even patients with diffuse large B-cell lymphoma who are eligible for chimeric antigen receptor (CAR) T-cell therapy face multiple barriers to care and need assistance.